Sinovac Biotech Co., Ltd.
Clinical trials sponsored by Sinovac Biotech Co., Ltd., explained in plain language.
Vaccine developer and manufacturer, known for COVID-19 vaccine CoronaVac.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Polio vaccine showdown: which sequence protects best? Results expected Sep 2026 (estimated)
- Rabies vaccine batch check: will it pass the test? Results expected Sep 2026 (estimated) 🚀 Make-or-break
- New meningitis vaccine for kids shows promise in large trial Results expected Nov 2026 (estimated) 🚀 Make-or-break
- New meningitis vaccine for toddlers shows promise in major trial Results expected Jan 2027 (estimated) 🚀 Make-or-break
- Can a vaccine shield children from severe hand, foot, and mouth disease? Results expected Jan 2027 (estimated)
-
Can a new vaccine shield more people from hepatitis a?
Vaccine Recruiting nowThis trial tests an inactivated hepatitis A vaccine called Healive in healthy people aged 1 year and older. Researchers will measure how well the vaccine triggers protective antibodies and check its safety. Adults receive the vaccine in an open-label group, while children are ran…
Phase 3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Aug 30, 2026 00:00 UTC
-
New meningitis vaccine trial aims to shield babies from deadly infection
Vaccine Recruiting nowThis Phase 3 trial tests a new vaccine designed to protect infants aged 3 to 5 months against four strains of meningococcal bacteria that cause meningitis and sepsis. About 880 healthy babies will receive either the experimental vaccine or a licensed comparator vaccine. Researche…
Phase 3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Aug 12, 2026 00:00 UTC
-
New meningitis vaccine for toddlers shows promise in major trial
Vaccine Recruiting nowThis study tests a new vaccine to protect young children (12-23 months old) against four types of meningococcal bacteria that can cause meningitis. About 1,040 toddlers will receive either the new vaccine or an existing one to see if the new vaccine is as safe and effective. The …
Phase 3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Aug 12, 2026 00:00 UTC
-
New meningitis vaccine trial aims to protect babies
Vaccine Recruiting nowThis Phase 3 trial tests a new vaccine against four types of meningococcal bacteria (A, C, Y, W135) that cause meningitis. About 1,040 healthy infants aged 6 to 11 months will receive either the experimental vaccine or a licensed comparator. Researchers will measure immune respon…
Phase 3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Aug 12, 2026 00:00 UTC
-
Polio vaccine showdown: which sequence protects best?
Vaccine Recruiting nowThis study tests two types of inactivated polio vaccine (Sabin strain and wild strain) given in different orders to 480 infants aged 2 months. The goal is to see which sequence triggers the best immune response and causes the fewest side effects. Participants will receive three d…
Phase 4 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Jun 27, 2026 11:00 UTC
-
MRNA vaccine aims to prevent shingles in older adults
Vaccine Recruiting nowThis study is testing a new mRNA vaccine to prevent shingles (herpes zoster) in adults aged 40 and older. The vaccine uses mRNA technology, similar to some COVID-19 vaccines, and is freeze-dried for easier storage. Researchers will compare different doses against existing vaccine…
Phase 1/2 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Jun 27, 2026 09:04 UTC
-
New flu vaccine trial aims to protect moms and babies
Vaccine Recruiting nowThis study tests a new flu vaccine in 150 healthy pregnant women aged 18-39, between 20 and 32 weeks of pregnancy. Participants receive either the new vaccine or an existing one, and researchers check immune response and safety for both mother and baby. The goal is to see if the …
Phase 3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
One polio shot enough? new trial tests simpler vaccine schedule
Vaccine Recruiting nowThis phase 4 study compares a single dose of an inactivated polio vaccine (sIPV) in people aged 7 to 50 years with the standard three-dose series given to infants. Researchers want to see if one shot can produce a similar immune response. The trial is recruiting 180 healthy parti…
Phase 4 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Jun 27, 2026 08:12 UTC